SUPN

Supernus Pharmaceuticals, Inc.
Data: 2026-09-11
$41.64
Price
-0.12%
Change
$59.68
52W High
$41.11
52W Low
Analyzing positioning… Options positioning — based on yesterday's biggest open-interest changes See the chart Institutional flows
Track record
signal day → next-day price move
Quick Stats
Sep 11, 2026

42.2

AI Score

HOLD

0.81

Volume Ratio

Nov 03, 2026

Next Earnings

9

+ve Days (30d)

20

-ve Days (30d)

SUPN Price vs Max Options Open Interest

How to read this: the line is the stock price; the bars show where the most option open interest sits each day. Strikes with heavy open interest often act as magnets or barriers for price ("max pain" zones). Scroll right for the most recent days.

SUPN Max Change In Options Open Interest

How to read this: each bar is the option contract whose open interest changed the most yesterday. Green bars = new positions being opened (conviction building at that strike); red bars = positions being closed. Call builds above the current price suggest upside bets; put builds below it suggest hedging or downside bets.

SUPN Options - Sort by Max open Interest (near term)

13th September 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

SUPN Daily Out of Money Options - Sort by Max open Interest (near term)

13th September 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

SUPN Daily In the Money Options - Sort by Max open Interest (near term)

13th September 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

SUPN Most Active Options by Volume(near term)

13th September 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI
Ask PC Delta Vega Volatility % change Track
SUPN Technical Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select an indicator above — it will be added as a pane under the price chart with aligned dates.

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

SUPN Stock Summary

Last updated Sep 11, 2026

SUPN is currently trading at $41.64, positioned below its 200-day moving average of $48.44, suggesting bearish momentum. The stock has a 52-week range of $41.11 to $59.68.

Technical Analysis: The 50-day moving average stands at $46.27, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 30.898, suggesting the stock is neutral with balanced momentum.

Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.294, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates SUPN at 42.2/100 with a HOLD recommendation.

SUPN (Supernus Pharmaceuticals, Inc.) Indicators

Last updated Sep 11, 2026

Indicator Value
RSI(14) 30.898
CMF (20) -0.294
ROC (10) -5.771
ADX (14) 23.663
Indicator Value
MACD (12,26,9) -1.234
AROONOSC (14) -92.857
WILLAMS %R (14) -88.842
MFI (14) 32.668

SUPN Candlestick Patterns

Validated patterns fired in the last 10 sessions. Hit rate = how often price moved in the signal's direction within 5 trading days (backtest: 2.7M signals, 3,500 liquid stocks, Feb 2025–Sep 2026). Baseline: a random stock closes higher 5 days later 53% of the time. Click a row to see the candle on the chart.

Date Pattern Signal 5-Day Hit Rate Edge vs Baseline Sample
Sep 08 Marubozu (bearish) (contrarian — textbook says the opposite) Bullish 56.2% +3.2 pts 30540
Sep 04 Gravestone Doji Bullish 55.2% +2.2 pts 21200
Sep 04 Inverted Hammer Bullish 56.4% +3.4 pts 19834
Aug 31 Gap Three Methods (bearish) (contrarian — textbook says the opposite) Bullish 56.1% +3.0 pts 4558

These are statistical tilts, not standalone trade setups. Only patterns with a measured edge are shown — roughly 50 of 60 textbook patterns showed no edge and are hidden.

Supernus Pharmaceuticals, Inc. is below both the 50 Day and 200 Day SMA which is considered Bearish.

SUPN Moving Averages Analysis

SUPN (Supernus Pharmaceuticals, Inc.) Simple Moving Averages

Moving Averages are last updated Sep 11, 2026

Days MA
10 43.1
20 44.9
30 45.41
50 46.27
100 46.8
200 48.44

SUPN Fundamental Analysis

P/E (Forward) 20.1613
P/E (Trailing) --
Market Cap ($) 2.4 billion
Earnings/Share ($) -1.9
Net Profit Margin (%) -0.1323
Dividend/Share ($) --
EPS Estimate Current Year ($) 2.565
EPS Estimate Next Year ($) 4.46
WallStreet Target Price ($) 61.75
Most Recent Quarter

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.